Disease overview

Alterations

133

Molecular (A)

100

Clinical (B–E)

Direct drugs

263

Via biomarker

204

Natural agents

Natural products

108

Merged ranked

465

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery

Best-intervention remission

NSCLC with driver mutations (EGFR, ALK, ROS1, MET, KRAS G12C): targeted therapy achieves 70-90% response rates; PFS 16-19 months with osimertinib (FLAURA2 combination up to 25 months); immunotherapy (pembrolizumab): 5-year OS ~31% in high PD-L1 expressers vs ~16% chemotherapy; SBRT for early-stage inoperable: 80-90% local control at 3 years

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large between targeted/immunotherapy eligible and chemotherapy-only; large between treated and screened populations

Primary barrier

access/practice

Barrier detail: Biomarker testing (PD-L1, EGFR/ALK/ROS1 mutations) still not universal; only 5-6% of high-risk smokers undergo low-dose CT screening despite 20% mortality reduction (NLST trial); smoking cessation dramatically reduces incidence but is underfunded

Last SoC change: 2023 — osimertinib adjuvant ADAURA (Stage IB-IIIA EGFR+ NSCLC) standard of care; neoadjuvant chemo-immunotherapy (CheckMate 816) plus surgery now standard for resectable stage III; PD-1/PD-L1 inhibitors first-line since 2016-2018; targeted therapy since 2010 (erlotinib)

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0008903 · ORPHA: ORPHA:289539

Alterations

133 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Alveolar cell carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chest pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cough	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dyspnea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Fever	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hemoptysis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypertension	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Lung adenocarcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Medulloblastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Multicystic kidney dysplasia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the lung	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Non-small cell lung carcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pleuropulmonary blastoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary fibrosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary infiltrates	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Recurrent pneumonia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Recurrent respiratory infections	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Rhabdomyosarcoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Wheezing	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATR ATR checkpoint kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA1 BRCA1 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BTK Bruton tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCDC6 coiled-coil domain containing 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD274 CD274 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD74 CD74 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK4 cyclin dependent kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK6 cyclin dependent kinase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTLA4 cytotoxic T-lymphocyte associated protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DHFR dihydrofolate reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DICER1 dicer 1, ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Duration in Treatment Benefit (Weeks) From Baseline Over 12 Weeks in Body Weight (≥0 kg)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Duration of Response (DOR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in 5-IASS (≥0 Points)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EML4 EMAP like 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EP300 EP300 lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB2 erb-b2 receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB3 erb-b2 receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAT1 FAT atypical cadherin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR1 fibroblast growth factor receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR3 fibroblast growth factor receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR4 fibroblast growth factor receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT4 fms related receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GART phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole syntheta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HGF hepatocyte growth factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDM6A lysine demethylase 6A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KEAP1 kelch like ECH associated protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIF5B kinesin family member 5B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2C lysine methyltransferase 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2D lysine methyltransferase 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRP1B LDL receptor related protein 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP2K1 mitogen-activated protein kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MET MET proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NF1 neurofibromin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFE2L2 NFE2 like bZIP transcription factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH1 notch receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH2 notch receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NPM1 nucleophosmin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRG1 neuregulin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK1 neurotrophic receptor tyrosine kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK2 neurotrophic receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NTRK3 neurotrophic receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overall survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PALB2 partner and localizer of BRCA2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDCD1 programmed cell death 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRA platelet derived growth factor receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRB platelet derived growth factor receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA2 DNA polymerase alpha 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD2 DNA polymerase delta 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE DNA polymerase epsilon, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE2 DNA polymerase epsilon 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POT1 protection of telomeres 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRIM2 DNA primase subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTEN phosphatase and tensin homolog	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Percentage of Participants With Adverse Events (AEs)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Procedure time	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Progression free survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
RB1 RB transcriptional corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RBM10 RNA binding motif protein 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RET ret proto-oncogene	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ROS1 ROS proto-oncogene 1, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM1 ribonucleotide reductase catalytic subunit M1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM2 ribonucleotide reductase regulatory subunit M2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM2B ribonucleotide reductase regulatory TP53 inducible subunit M2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SDC4 syndecan 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SETD2 SET domain containing 2, histone lysine methyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SRC SRC proto-oncogene, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
STK11 serine/threonine kinase 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TERT telomerase reverse transcriptase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TOP1 DNA topoisomerase I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TOP2A DNA topoisomerase II alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TP53 tumor protein p53	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TP63 tumor protein p63	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1A tubulin alpha 1a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1B tubulin alpha 1b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA1C tubulin alpha 1c	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA3C tubulin alpha 3c	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA3E tubulin alpha 3e	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBA4A tubulin alpha 4a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB tubulin beta class I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB1 tubulin beta 1 class VI	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2A tubulin beta 2A class IIa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB2B tubulin beta 2B class IIb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB3 tubulin beta 3 class III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB4A tubulin beta 4A class IVa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB4B tubulin beta 4B class IVb	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB6 tubulin beta 6 class V	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TUBB8 tubulin beta 8 class VIII	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYMS thymidylate synthetase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Time to extracranial disease progression	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Time to progression	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
U2AF1 U2 small nuclear RNA auxiliary factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VEGFA vascular endothelial growth factor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
arterial blood oxygen partial pressure (PaO2)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
safety	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
venous blood oxygen partial pressure (PvO2)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
NICOTINE	Small molecule	Approved	Strong	100	8 trials 7 Cochrane 13 Meta-analysis 51 Trial pubs 45 RCT View evidence Registry trials NCT00310141 — Computer-Assisted Counseling in Helping African American Smokers Stop Smoking (COMPLETED) NA NCT07111936 — Evaluating the Impact of CONNECT in a Multilingual Population (NOT_YET_RECRUITING) NA NCT01434342 — Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients (COMPLETED) EARLY_PHASE1 NCT03200236 — The Lung Screening, Tobacco and Health Project (COMPLETED) PHASE3 NCT00957424 — Acceptability of Less Harmful Alternatives to Cigarettes (COMPLETED) NA NCT04616768 — PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers (COMPLETED) PHASE3 NCT02658032 — Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP) (COMPLETED) NA NCT01176383 — Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers (COMPLETED) NA Published literature Cochrane review Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map (Addiction (Abingdon, England), 2026) Cochrane review Health impacts of passive exposure to alternative tobacco products: a systematic review (Respiratory medicine, 2026) Cochrane review Interventions for smoking cessation in people diagnosed with lung cancer (The Cochrane database of systematic reviews, 2019) Cochrane review A Systematic Review of Effects of Waterpipe Smoking on Cardiovascular and Respiratory Health Outcomes (Tobacco use insights, 2016) Cochrane review Benefits of E-Cigarettes Among Heavy Smokers Undergoing a Lung Cancer Screening Program: Randomized Controlled Trial Protocol (JMIR research protocols, 2016) Meta-analysis Tar level of cigarettes smoked and risk of smoking-related diseases (Inhalation toxicology, 2018) Meta-analysis Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence (Molecular psychiatry, 2018) Meta-analysis Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis (EBioMedicine, 2016) Meta-analysis Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence (Translational psychiatry, 2015) Meta-analysis Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans (Molecular psychiatry, 2016) Systematic review Evidence on vaping e-cigarettes as a risk factor for cancer: A systematic review (Journal of cancer policy, 2025) Systematic review Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review (Clinical lung cancer, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SIROLIMUS	Small molecule	Approved	Strong	100	8 trials 6 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT00807755 — Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors (TERMINATED) PHASE1 NCT01175096 — Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (UNKNOWN) PHASE1, PHASE2 NCT02061800 — CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00375245 — Rapamycin With Grapefruit Juice for Advanced Malignancies (COMPLETED) PHASE1 NCT02920450 — Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) (TERMINATED) PHASE1, PHASE2 NCT00921310 — Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (TERMINATED) PHASE1, PHASE2 NCT02432560 — Safety and Durability of Sirolimus for Treatment of LAM (RECRUITING) Published literature Clinical trial publication A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib (Lung cancer (Amsterdam, Netherlands), 2017) Clinical trial publication Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial (Blood, 2015) Clinical trial publication Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population (Oncotarget, 2013) Clinical trial publication A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors (Japanese journal of clinical oncology, 2010) Clinical trial publication Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIGENIN Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women (The American journal of clinical nutrition, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BLEOMYCIN Repurposing	Small molecule	Approved	Strong	95	4 trials 4 Meta-analysis 23 Trial pubs 11 RCT View evidence Registry trials NCT05427136 — Early Pulmonary Dysfunction in Childhood Cancer Patients (RECRUITING) NCT00165438 — Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy (COMPLETED) NCT01660399 — Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy (UNKNOWN) PHASE2 NCT00132613 — Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion (COMPLETED) PHASE3 Published literature Meta-analysis Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis (Scientific reports, 2024) Meta-analysis Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021) Meta-analysis 15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers (Journal of the National Cancer Institute, 2015) Meta-analysis Herbal extract elemene intrathoracic injection in the treatment of lung cancer patients with malignant pleural effusion: a meta-anaylsis (Journal of cancer research and therapeutics, 2014) Systematic review Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review (Bulletin du cancer, 2020) Clinical trial publication Ablation of soft tissue tumours by long needle variable electrode-geometry electrochemotherapy: final report from a single-arm, single-centre phase-2 study (Scientific reports, 2020) Clinical trial publication Telomerase and telomere length in pulmonary fibrosis (American journal of respiratory cell and molecular biology, 2013) Clinical trial publication A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) (British journal of cancer, 2009) Clinical trial publication Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515 (Lung cancer (Amsterdam, Netherlands), 2007) Clinical trial publication Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007) Randomized controlled trial Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy (Seminars in oncology, 2005) Randomized controlled trial [Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone] (Pneumologie (Stuttgart, Germany), 1997) CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 32 Cochrane 51 Meta-analysis 1669 Trial pubs 722 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00003657 — High-dose ICE With Amifostine (COMPLETED) PHASE2 NCT00072527 — Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (COMPLETED) PHASE2 NCT02299765 — Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (TERMINATED) PHASE4 NCT00528619 — A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT03711305 — Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (UNKNOWN) PHASE3 NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT01563601 — Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer (WITHDRAWN) PHASE3 Published literature Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Clinical pharmacology in drug development, 2025) Cochrane review Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis (Heliyon, 2024) Cochrane review Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis (Frontiers in medicine, 2023) Cochrane review Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status (The Cochrane database of systematic reviews, 2023) Meta-analysis The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials (World journal of surgical oncology, 2025) Meta-analysis First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis (Journal of cancer research and therapeutics, 2023) Meta-analysis Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis (Cancer medicine, 2023) Systematic review Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review (Frontiers in pharmacology, 2023) Systematic review The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data (Frontiers in immunology, 2023) Systematic review Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Frontiers in medicine, 2021) Clinical trial publication Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CERITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 77 Cochrane 118 Meta-analysis 2500 Trial pubs 1156 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00312819 — Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer (COMPLETED) PHASE2, PHASE3 NCT00072527 — Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (COMPLETED) PHASE2 NCT03891173 — A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (TERMINATED) PHASE2 NCT02797977 — A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (COMPLETED) PHASE1, PHASE2 NCT00528619 — A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT00891761 — A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (WITHDRAWN) PHASE3 NCT03781869 — Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer (UNKNOWN) PHASE2 Published literature Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials (World journal of surgical oncology, 2025) Cochrane review Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Clinical pharmacology in drug development, 2025) Cochrane review A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer (Medicine, 2024) Cochrane review Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis (Heliyon, 2024) Meta-analysis Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer (Cancer reports (Hoboken, N.J.), 2024) Meta-analysis Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis (Scientific reports, 2024) Systematic review Combating Drug Resistance in Lung Cancer: Exploring the Synergistic Potential of Metformin and Cisplatin in a Novel Combination Therapy; A Systematic Review (Current topics in medicinal chemistry, 2025) Systematic review Development and Update of Guideline-based Quality Indicators in Lung Cancer (Pneumologie (Stuttgart, Germany), 2024) Systematic review Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis (Frontiers in medicine, 2023) Systematic review Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status (The Cochrane database of systematic reviews, 2023) Clinical trial publication Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
COSIBELIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00634205 — Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma (COMPLETED) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT00003034 — ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen (UNKNOWN) PHASE3 NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00011921 — Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer (UNKNOWN) PHASE3 NCT00002822 — Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer (COMPLETED) PHASE3 NCT03678883 — 9-ING-41 in Patients With Advanced Cancers (ACTIVE_NOT_RECRUITING) PHASE2 NCT02566993 — Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DENOSUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing	Small molecule	Approved	Strong	95	4 Trial pubs View evidence Published literature Clinical trial publication Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer (Cancer biotherapy & radiopharmaceuticals, 2000) Clinical trial publication Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer (Clinical nuclear medicine, 1999) Clinical trial publication High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncológico Cooperativo del Sur study (American journal of clinical oncology, 1995) Clinical trial publication Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188 (Journal of the National Cancer Institute, 1988) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials 6 Trial pubs 1 RCT View evidence Registry trials NCT00634205 — Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma (COMPLETED) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT03808480 — Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (UNKNOWN) PHASE2 NCT00003034 — ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen (UNKNOWN) PHASE3 NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00011921 — Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer (UNKNOWN) PHASE3 NCT00002822 — Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer (COMPLETED) PHASE3 NCT00041808 — Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer (Clinical lung cancer, 2003) Clinical trial publication A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer (Chest, 1997) Clinical trial publication Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients (Journal of pharmaceutical sciences, 1993) Clinical trial publication Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood (British journal of cancer, 1993) Clinical trial publication Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study (Cancer, 1982) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN LIPOSOME Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DURVALUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENCORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENSARTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENTRECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENZALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERLOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOPOSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EVEROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FILGOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOROURACIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FULVESTRANT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FUTIBATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GEFITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GEMCITABINE Repurposing	Small molecule	Approved	Strong	95	8 trials 39 Cochrane 53 Meta-analysis 929 Trial pubs 390 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT02797977 — A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (COMPLETED) PHASE1, PHASE2 NCT02299765 — Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (TERMINATED) PHASE4 NCT05500092 — An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT02873416 — Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer (UNKNOWN) PHASE1, PHASE2 NCT02352948 — A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (COMPLETED) PHASE3 Published literature Cochrane review Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review (Frontiers in pharmacology, 2023) Cochrane review Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer (American journal of translational research, 2023) Cochrane review Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer (Frontiers in pharmacology, 2022) Cochrane review Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer (Journal of healthcare engineering, 2022) Cochrane review Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of non-small cell lung cancer (Journal of clinical pharmacy and therapeutics, 2022) Meta-analysis Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis (Pharmaceutical biology, 2021) Meta-analysis Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases (Annals of palliative medicine, 2020) Meta-analysis Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis (Clinical and translational science, 2020) Systematic review Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Frontiers in medicine, 2021) Clinical trial publication Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (Oncoimmunology, 2026) Clinical trial publication First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation (Chinese medical journal, 2026) Clinical trial publication Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313) (The oncologist, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
GILTERITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYCHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IDELALISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IFOSFAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IPILIMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IXAZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LAPATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LENVATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LORLATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIRDAMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOMYCIN Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 4 Meta-analysis 190 Trial pubs 109 RCT View evidence Registry trials NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT00004209 — Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (UNKNOWN) PHASE3 NCT04200417 — Chemoembolization for Lung Tumors (COMPLETED) PHASE1 NCT00148395 — Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. (COMPLETED) PHASE3 NCT01953406 — The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma (WITHDRAWN) PHASE2 NCT00003159 — Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer (COMPLETED) PHASE3 NCT05672108 — Phase II Trial of Lung Chemoemobolization (RECRUITING) PHASE2 NCT00128037 — Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806) (COMPLETED) PHASE2 Published literature Cochrane review A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer (BMC cancer, 2022) Cochrane review [Kanglaite for Treating Advanced Non-small-cell Lung Cancer: A Systematic Review.] (Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2009) Meta-analysis The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature (British journal of cancer, 2001) Meta-analysis The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group (Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1999) Meta-analysis The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective (Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1996) Clinical trial publication Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial (JAMA oncology, 2021) Clinical trial publication Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair (Journal of the National Cancer Institute, 2016) Clinical trial publication Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011) Clinical trial publication Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Clinical trial publication Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Randomized controlled trial Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial (Complementary therapies in medicine, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOTANE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	2 trials View evidence Registry trials NCT02467426 — Isolated Thoracic Perfusion (ITP-F) for MPM (COMPLETED) NCT04352413 — A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NERATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NIRAPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 4 Trial pubs 1 RCT View evidence Registry trials NCT04701307 — Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas (ACTIVE_NOT_RECRUITING) PHASE2 NCT03654833 — Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (UNKNOWN) PHASE2 NCT03308942 — Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants (COMPLETED) PHASE2 NCT05169437 — Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (TERMINATED) PHASE2 NCT05455424 — Niraparib Efficacy in Patient With Unresectable Mesothelioma (COMPLETED) PHASE2 NCT03830918 — Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT03891615 — Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer (UNKNOWN) PHASE1 NCT05718323 — Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RECRUITING) PHASE2 Published literature Clinical trial publication Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial (Clinical cancer research : an official journal of the American Association for Cancer Research, 2024) Clinical trial publication JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer (Cancer, 2022) Clinical trial publication Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021) Clinical trial publication The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial (The Lancet. Oncology, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
NIVOLUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 1 Cochrane 19 Trial pubs 5 RCT View evidence Registry trials NCT06419179 — Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (ENROLLING_BY_INVITATION) PHASE2 NCT02734004 — A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT06217757 — Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC (RECRUITING) PHASE1, PHASE2 NCT05975944 — Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer (UNKNOWN) PHASE1, PHASE2 NCT05623319 — Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (RECRUITING) PHASE2 NCT03155620 — Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (ACTIVE_NOT_RECRUITING) PHASE2 NCT02769962 — Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (COMPLETED) PHASE1, PHASE2 NCT04939662 — Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (COMPLETED) PHASE2 Published literature Cochrane review First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis (Frontiers in oncology, 2024) Systematic review Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis (Frontiers in oncology, 2025) Clinical trial publication Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (JCO precision oncology, 2026) Clinical trial publication Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study (JCO precision oncology, 2025) Clinical trial publication Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial (Targeted oncology, 2024) Randomized controlled trial Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial (British journal of cancer, 2024) Randomized controlled trial Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial (Lung cancer (Amsterdam, Netherlands), 2022) Randomized controlled trial Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial (Clinical cancer research : an official journal of the American Association for Cancer Research, 2022) Randomized controlled trial Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) (Lung cancer (Amsterdam, Netherlands), 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
OSIMERTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXALIPLATIN Repurposing	Small molecule	Approved	Strong	95	8 trials 3 Cochrane 4 Meta-analysis 42 Trial pubs 15 RCT View evidence Registry trials NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT05576077 — A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT04043195 — Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT03250832 — Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (COMPLETED) PHASE1 NCT06131840 — A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (RECRUITING) PHASE1 NCT06835569 — A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations (RECRUITING) PHASE1 NCT03009058 — Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (TERMINATED) PHASE1, PHASE2 NCT06047379 — Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model (Health technology assessment (Winchester, England), 2013) Cochrane review [Vinorelbine plus oxaliplatin versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: a systematic review] (Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010) Cochrane review KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (Ontario health technology assessment series, 2010) Meta-analysis The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis (International immunopharmacology, 2022) Meta-analysis The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets (Oncotarget, 2017) Meta-analysis Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer (Medicine, 2015) Meta-analysis [Oxaliplatin: the first DACH platinum in clinical practice] (Bulletin du cancer, 1997) Systematic review Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis (Frontiers in oncology, 2019) Clinical trial publication Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial (JNCI cancer spectrum, 2025) Clinical trial publication Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01) (Anticancer research, 2021) Clinical trial publication A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC) (Cancer chemotherapy and pharmacology, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
PACLITAXEL PROTEIN-BOUND Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT07271602 — A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (NOT_YET_RECRUITING) PHASE2 NCT05295212 — Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB (RECRUITING) PHASE2 NCT05500092 — An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT06449209 — Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT01814163 — Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab (COMPLETED) NCT07618793 — Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma (NOT_YET_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
PALBOCICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PANITUMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PANOBINOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMETREXED DISODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENPULIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERMETHRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERTUZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing	Small molecule	Approved	Strong	95	21 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PIRTOBRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PONATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALSETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RABEPRAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMUCIRUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REGORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIBRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REPOTRECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RESVERATROL Repurposing	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis View evidence Published literature Cochrane review Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis (Frontiers in nutrition, 2025) Meta-analysis Resveratrol in lung cancer- a systematic review (Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
RIBOCICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBOFLAVIN Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006) Clinical trial publication [Chemoprevention in the high incidence area of lung cancer] (Zhonghua zhong liu za zhi [Chinese journal of oncology], 1989) CT.gov search · Cochrane · PubMed	DGIdb	—
RIFAMPIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RILZABRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RITLECITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RITLECITINIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ROMIDEPSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RUCAPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT03654833 — Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (UNKNOWN) PHASE2 NCT03845296 — Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (COMPLETED) PHASE2 NCT04171700 — A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (TERMINATED) PHASE2 NCT02711137 — Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (TERMINATED) PHASE1, PHASE2 NCT03958045 — Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma (COMPLETED) PHASE2 NCT07674368 — Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed (NOT_YET_RECRUITING) PHASE4 NCT04209595 — PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (COMPLETED) PHASE1, PHASE2 NCT03559049 — Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer (TERMINATED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
RUXOLITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SACITUZUMAB GOVITECAN Repurposing	Small molecule	Approved	Strong	95	8 trials 4 Cochrane 1 Meta-analysis 8 Trial pubs 1 RCT View evidence Registry trials NCT04794699 — Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (ACTIVE_NOT_RECRUITING) PHASE1 NCT07339059 — Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (RECRUITING) PHASE2 NCT06477419 — A Study of Sacituzumab Govitecan in People With Mesothelioma (RECRUITING) PHASE2 NCT05633667 — Study of Novel Treatment Combinations in Patients With Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01631552 — Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (COMPLETED) PHASE1, PHASE2 NCT07393555 — Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) (NOT_YET_RECRUITING) PHASE2 NCT03337698 — A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (TERMINATED) PHASE1, PHASE2 NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (RECRUITING) PHASE3 Published literature Cochrane review Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis (Frontiers in pharmacology, 2025) Cochrane review TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes (Critical reviews in oncology/hematology, 2026) Cochrane review Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis (Frontiers in oncology, 2025) Cochrane review TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC) (Cancer treatment reviews, 2023) Clinical trial publication First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026) Clinical trial publication Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2-targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors (Drug metabolism and disposition: the biological fate of chemicals, 2025) Clinical trial publication The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan (Clinical lung cancer, 2025) Clinical trial publication Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
SAPANISERTIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SELPERCATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SUGEMALIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SUNVOZERTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing	Small molecule	Approved	Strong	95	8 trials 6 Trial pubs 1 RCT View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT02567396 — Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (WITHDRAWN) PHASE1 NCT03672773 — Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01286987 — Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (COMPLETED) PHASE1 NCT03377556 — Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (COMPLETED) PHASE2 NCT04462809 — Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (UNKNOWN) PHASE2 NCT02154490 — Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (COMPLETED) NCT04173507 — Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (COMPLETED) PHASE2 Published literature Clinical trial publication Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study (JCO precision oncology, 2024) Clinical trial publication Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G (Clinical lung cancer, 2021) Clinical trial publication Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol (The Lancet. Oncology, 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
TALETRECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMOXIFEN CITRATE Repurposing	Small molecule	Approved	Strong	95	4 trials View evidence Registry trials NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00847366 — Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma (COMPLETED) NA NCT00999921 — Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer (COMPLETED) PHASE4 NCT00896155 — Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
TAZEMETOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TEMOZOLOMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TEMSIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TEPOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THIABENDAZOLE Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TIRABRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TISLELIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIVOZANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TORIPALIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOVORAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAMETINIB DIMETHYL SULFOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRASTUZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TREMELIMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALPROIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VANDETANIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VEMURAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VINBLASTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VINCRISTINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VINORELBINE Repurposing	Small molecule	Approved	Strong	95	8 trials 32 Cochrane 37 Meta-analysis 601 Trial pubs 253 RCT View evidence Registry trials NCT00312819 — Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer (COMPLETED) PHASE2, PHASE3 NCT03891173 — A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (TERMINATED) PHASE2 NCT02352948 — A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (COMPLETED) PHASE3 NCT00705549 — Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer (TERMINATED) PHASE2 NCT00001944 — Vinorelbine and XR9576 to Treat Cancer (COMPLETED) PHASE1 NCT02603003 — the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs (COMPLETED) PHASE1 NCT00522886 — Phase I Cetuximab and Concurrent Radio-chemotherapy (COMPLETED) PHASE1 NCT03456076 — A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE3 Published literature Cochrane review Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic review (Translational cancer research, 2026) Cochrane review A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer (Medicine, 2024) Cochrane review Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses (BMC cancer, 2024) Cochrane review Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer (Frontiers in pharmacology, 2022) Cochrane review A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer (BMC cancer, 2022) Meta-analysis Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis (BMJ open, 2022) Meta-analysis Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data (BMC pulmonary medicine, 2022) Systematic review Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis (Lung cancer (Amsterdam, Netherlands), 2019) Systematic review Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials (Cytotherapy, 2019) Systematic review Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review (Clinical oncology (Royal College of Radiologists (Great Britain)), 2019) Systematic review Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review (Expert review of anticancer therapy, 2018) Clinical trial publication Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis (European journal of cancer (Oxford, England : 1990), 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
VORINOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ZANUBRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ZOLEDRONIC ACID ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABEMACICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BERAHYALURONIDASE ALFA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIMESNA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPILIMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KARENITECIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARIMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NECITUMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCILETINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TANOMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARLATAMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
URIDINE TRIPHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VIBOSTOLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTINEOPLASTON A10	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AUMOLERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXELOPRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZACITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIVANIB ALANINATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERTOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DABRAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DICLOFENAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECADOTRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENALAPRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIRMONERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMISTOTUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GRAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDARUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAZERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOBUPIVACAINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLAPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXAZOLIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PATRITUMAB DERUXTECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAXALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGENZILEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PHENYLACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLICAMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONATINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RANPIRNASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RELATLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SALIRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIRACIL HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TYROSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK126 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
M4344 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
2X-121	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALVOCIDIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AURANOFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BATOPROTAFIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINTRAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIW-8962	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986156	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRIGIMADLIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BT-5528	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUDESONIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CABIRALIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAROTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CERITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CETUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACOMITINIB ANHYDROUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DARLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DAVAMOTECAN PEGADEXAMER	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIAZEPINOMICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOTMP SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ETHIODIZED OIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EXARAFENIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EZABENLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FIANLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALUNISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GEBASAXTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IBI-939	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDRONOXIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMMUNOCYTOKINE NHS-IL12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISTIRATUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
L-DOS47	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANERKITUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAPACHONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINSITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LORLATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LURTOTECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOGAMULIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NANRILKEFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVITOCLAX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEO-201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEROFE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NY-ESO-1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONVATILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PADELIPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMETREXED DISODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMLIMOGENE MEROLISBAC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEXIPEPIMUT-S	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PORFIMER SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REFAMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGORAFENIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG-4733	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SASANLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SEPHB4-HSA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOTIGALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENATUMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
THIOSULFURIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFCEMALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUCOTUZUMAB CELMOLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOCIPROTAFIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XENTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALECTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLMUTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRINOMASTAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BERAHYALURONIDASE ALFA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEVACIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CAPMATINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CUSTIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIMESNA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPILIMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KARENITECIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LURBINECTEDIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MARIMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NECITUMUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OSIMERTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCILETINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SINTILIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SOTORASIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TANOMASTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARLATAMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOPOTECAN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
URIDINE TRIPHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VIBOSTOLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINORELBINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
(+/-)NICOTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAGRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEBRELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AGATOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTINEOPLASTON A10	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APATORSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASCORBIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AUMOLERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AXELOPRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZACITIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BORTEZOMIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRIVANIB ALANINATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BROMELAINS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABAZITAXEL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CABOZANTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CATEQUENTINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CERTOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DABRAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DALPICICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DICLOFENAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECADOTRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELRAGLUSIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENALAPRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENDOSTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTINOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENTRECTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EVEROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FIRMONERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FULVESTRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GIMISTOTUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GRAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ICOTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDARUBICIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRINOTECAN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAPATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAZERTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENVATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LETROZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOBUPIVACAINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMUSTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUCITANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NELFINAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NICOTINE	Small molecule	Phase II	Emerging	60	8 trials 7 Cochrane 13 Meta-analysis 51 Trial pubs 45 RCT View evidence Registry trials NCT00310141 — Computer-Assisted Counseling in Helping African American Smokers Stop Smoking (COMPLETED) NA NCT07111936 — Evaluating the Impact of CONNECT in a Multilingual Population (NOT_YET_RECRUITING) NA NCT01434342 — Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients (COMPLETED) EARLY_PHASE1 NCT03200236 — The Lung Screening, Tobacco and Health Project (COMPLETED) PHASE3 NCT00957424 — Acceptability of Less Harmful Alternatives to Cigarettes (COMPLETED) NA NCT04616768 — PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers (COMPLETED) PHASE3 NCT02658032 — Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP) (COMPLETED) NA NCT01176383 — Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers (COMPLETED) NA Published literature Cochrane review Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map (Addiction (Abingdon, England), 2026) Cochrane review Health impacts of passive exposure to alternative tobacco products: a systematic review (Respiratory medicine, 2026) Cochrane review Interventions for smoking cessation in people diagnosed with lung cancer (The Cochrane database of systematic reviews, 2019) Cochrane review A Systematic Review of Effects of Waterpipe Smoking on Cardiovascular and Respiratory Health Outcomes (Tobacco use insights, 2016) Cochrane review Benefits of E-Cigarettes Among Heavy Smokers Undergoing a Lung Cancer Screening Program: Randomized Controlled Trial Protocol (JMIR research protocols, 2016) Meta-analysis Tar level of cigarettes smoked and risk of smoking-related diseases (Inhalation toxicology, 2018) Meta-analysis Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence (Molecular psychiatry, 2018) Meta-analysis Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis (EBioMedicine, 2016) Meta-analysis Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence (Translational psychiatry, 2015) Meta-analysis Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans (Molecular psychiatry, 2016) Systematic review Evidence on vaping e-cigarettes as a risk factor for cancer: A systematic review (Journal of cancer policy, 2025) Systematic review Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review (Clinical lung cancer, 2024) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
NITROGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OLAPARIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXAZOLIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALBOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PATRITUMAB DERUXTECAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAXALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PAZOPANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGENZILEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIGATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PHENYLACETIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PLICAMYCIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PONATINIB HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PYROTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAMUCIRUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RANPIRNASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RELATLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RETASPIMYCIN HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SACUBITRIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SALIRASIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SARGRAMOSTIM	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SELUMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SORAFENIB TOSYLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIQUIDAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGTOCICLIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMOZOLOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPIRACIL HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRAMETINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRASTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TYROSINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALSARTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEMURAFENIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZANIDATAMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZOLEDRONIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
2X-121	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AFLIBERCEPT	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALVOCIDIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANASTROZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AURANOFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AVUTOMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BATOPROTAFIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINIMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BINTRAFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BIW-8962	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-986156	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BRIGIMADLIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BT-5528	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUDESONIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CABIRALIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAMPTOTHECIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAROTUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CEDIRANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CELECOXIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CERITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CETUXIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHARCOAL, ACTIVATED	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CRIZOTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DACOMITINIB ANHYDROUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DARLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DAVAMOTECAN PEGADEXAMER	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DECITABINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIAZEPINOMICIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOTMP SM-153	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ENFORTUMAB VEDOTIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERLOTINIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ETHIODIZED OIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EXARAFENIB HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EZABENLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC CARBOXYMALTOSE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERRIC OXYHYDROXIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FERROUS SULFATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FIANLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GALUNISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GEBASAXTUREV	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IBI-939	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDRONOXIL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMMUNOCYTOKINE NHS-IL12	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IRON ISOMALTOSIDE 1000	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ISTIRATUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
L-DOS47	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANERKITUG	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAPACHONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINSITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LORLATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LURTOTECAN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MOGAMULIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NANRILKEFUSP ALFA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVITOCLAX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEO-201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NEROFE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NINTEDANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIRAPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NY-ESO-1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONVATILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PADELIPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMETREXED DISODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMLIMOGENE MEROLISBAC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PEXIPEPIMUT-S	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PORFIMER SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REFAMETINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGORAFENIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG-4733	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RIVOCERANIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROMIDEPSIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAMOTOLISIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SAPANISERTIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SASANLIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SEPHB4-HSA	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SERIBANTUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase I	Emerging	35	8 trials 6 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT00807755 — Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors (TERMINATED) PHASE1 NCT01175096 — Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (UNKNOWN) PHASE1, PHASE2 NCT02061800 — CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00375245 — Rapamycin With Grapefruit Juice for Advanced Malignancies (COMPLETED) PHASE1 NCT02920450 — Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) (TERMINATED) PHASE1, PHASE2 NCT00921310 — Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (TERMINATED) PHASE1, PHASE2 NCT02432560 — Safety and Durability of Sirolimus for Treatment of LAM (RECRUITING) Published literature Clinical trial publication A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib (Lung cancer (Amsterdam, Netherlands), 2017) Clinical trial publication Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial (Blood, 2015) Clinical trial publication Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population (Oncotarget, 2013) Clinical trial publication A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors (Japanese journal of clinical oncology, 2010) Clinical trial publication Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SORAFENIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SOTIGALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SUNITINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TEGAFUR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TENATUMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
THIOSULFURIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIFCEMALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TUCOTUZUMAB CELMOLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALEMETOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VELIPARIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VERTEPORFIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOCIPROTAFIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VORINOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XENTUZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALECTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CEMIPLIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXMEDETOMIDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEUPROLIDE ACETATE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHOTREXATE SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIRTAZAPINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEDAPLATIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLMUTINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PENPULIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRINOMASTAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRAMETINIB DIMETHYL SULFOXIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB MALEATE Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIGENIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women (The American journal of clinical nutrition, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BLEOMYCIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	4 trials 4 Meta-analysis 23 Trial pubs 11 RCT View evidence Registry trials NCT05427136 — Early Pulmonary Dysfunction in Childhood Cancer Patients (RECRUITING) NCT00165438 — Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy (COMPLETED) NCT01660399 — Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy (UNKNOWN) PHASE2 NCT00132613 — Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion (COMPLETED) PHASE3 Published literature Meta-analysis Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis (Scientific reports, 2024) Meta-analysis Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021) Meta-analysis 15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers (Journal of the National Cancer Institute, 2015) Meta-analysis Herbal extract elemene intrathoracic injection in the treatment of lung cancer patients with malignant pleural effusion: a meta-anaylsis (Journal of cancer research and therapeutics, 2014) Systematic review Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review (Bulletin du cancer, 2020) Clinical trial publication Ablation of soft tissue tumours by long needle variable electrode-geometry electrochemotherapy: final report from a single-arm, single-centre phase-2 study (Scientific reports, 2020) Clinical trial publication Telomerase and telomere length in pulmonary fibrosis (American journal of respiratory cell and molecular biology, 2013) Clinical trial publication A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) (British journal of cancer, 2009) Clinical trial publication Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515 (Lung cancer (Amsterdam, Netherlands), 2007) Clinical trial publication Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007) Randomized controlled trial Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy (Seminars in oncology, 2005) Randomized controlled trial [Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone] (Pneumologie (Stuttgart, Germany), 1997) CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 32 Cochrane 51 Meta-analysis 1669 Trial pubs 722 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00003657 — High-dose ICE With Amifostine (COMPLETED) PHASE2 NCT00072527 — Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (COMPLETED) PHASE2 NCT02299765 — Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (TERMINATED) PHASE4 NCT00528619 — A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT03711305 — Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (UNKNOWN) PHASE3 NCT06400472 — A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (RECRUITING) PHASE1 NCT01563601 — Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer (WITHDRAWN) PHASE3 Published literature Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Clinical pharmacology in drug development, 2025) Cochrane review Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis (Heliyon, 2024) Cochrane review Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis (Frontiers in medicine, 2023) Cochrane review Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status (The Cochrane database of systematic reviews, 2023) Meta-analysis The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials (World journal of surgical oncology, 2025) Meta-analysis First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis (Journal of cancer research and therapeutics, 2023) Meta-analysis Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis (Cancer medicine, 2023) Systematic review Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review (Frontiers in pharmacology, 2023) Systematic review The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data (Frontiers in immunology, 2023) Systematic review Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Frontiers in medicine, 2021) Clinical trial publication Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CELECOXIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
CERITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 77 Cochrane 118 Meta-analysis 2500 Trial pubs 1156 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT00312819 — Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer (COMPLETED) PHASE2, PHASE3 NCT00072527 — Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer (COMPLETED) PHASE2 NCT03891173 — A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (TERMINATED) PHASE2 NCT02797977 — A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (COMPLETED) PHASE1, PHASE2 NCT00528619 — A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors (COMPLETED) PHASE1 NCT00891761 — A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (WITHDRAWN) PHASE3 NCT03781869 — Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer (UNKNOWN) PHASE2 Published literature Cochrane review A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall-cell Lung Cancer in India (Indian journal of public health, 2026) Cochrane review Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials (World journal of surgical oncology, 2025) Cochrane review Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Clinical pharmacology in drug development, 2025) Cochrane review A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer (Medicine, 2024) Cochrane review Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis (Heliyon, 2024) Meta-analysis Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer (Cancer reports (Hoboken, N.J.), 2024) Meta-analysis Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis (Scientific reports, 2024) Systematic review Combating Drug Resistance in Lung Cancer: Exploring the Synergistic Potential of Metformin and Cisplatin in a Novel Combination Therapy; A Systematic Review (Current topics in medicinal chemistry, 2025) Systematic review Development and Update of Guideline-based Quality Indicators in Lung Cancer (Pneumologie (Stuttgart, Germany), 2024) Systematic review Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis (Frontiers in medicine, 2023) Systematic review Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status (The Cochrane database of systematic reviews, 2023) Clinical trial publication Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial (The Lancet. Oncology, 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
COSIBELIMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DAUNORUBICIN HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00634205 — Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma (COMPLETED) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT00003034 — ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen (UNKNOWN) PHASE3 NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00011921 — Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer (UNKNOWN) PHASE3 NCT00002822 — Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer (COMPLETED) PHASE3 NCT03678883 — 9-ING-41 in Patients With Advanced Cancers (ACTIVE_NOT_RECRUITING) PHASE2 NCT02566993 — Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DENOSUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing via BRCA1	Small molecule	Approved	Strong	95	4 Trial pubs View evidence Published literature Clinical trial publication Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer (Cancer biotherapy & radiopharmaceuticals, 2000) Clinical trial publication Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer (Clinical nuclear medicine, 1999) Clinical trial publication High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncológico Cooperativo del Sur study (American journal of clinical oncology, 1995) Clinical trial publication Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188 (Journal of the National Cancer Institute, 1988) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 6 Trial pubs 1 RCT View evidence Registry trials NCT00634205 — Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma (COMPLETED) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT03808480 — Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (UNKNOWN) PHASE2 NCT00003034 — ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen (UNKNOWN) PHASE3 NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00011921 — Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer (UNKNOWN) PHASE3 NCT00002822 — Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer (COMPLETED) PHASE3 NCT00041808 — Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver (COMPLETED) PHASE1, PHASE2 Published literature Clinical trial publication A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer (Clinical lung cancer, 2003) Clinical trial publication A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer (Chest, 1997) Clinical trial publication Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients (Journal of pharmaceutical sciences, 1993) Clinical trial publication Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood (British journal of cancer, 1993) Clinical trial publication Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study (Cancer, 1982) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN LIPOSOME Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DURVALUMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
ENCORAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ENSARTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
ENTRECTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
ENZALUTAMIDE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERLOTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ETHOXZOLAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOPOSIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
EVEROLIMUS Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
FILGOTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUDARABINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOROURACIL Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
FULVESTRANT Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
FUTIBATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
GEFITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
GEMCITABINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 39 Cochrane 53 Meta-analysis 929 Trial pubs 390 RCT View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT02797977 — A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (COMPLETED) PHASE1, PHASE2 NCT02299765 — Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (TERMINATED) PHASE4 NCT05500092 — An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT02873416 — Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer (UNKNOWN) PHASE1, PHASE2 NCT02352948 — A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (COMPLETED) PHASE3 Published literature Cochrane review Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review (Frontiers in pharmacology, 2023) Cochrane review Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer (American journal of translational research, 2023) Cochrane review Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer (Frontiers in pharmacology, 2022) Cochrane review Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer (Journal of healthcare engineering, 2022) Cochrane review Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of non-small cell lung cancer (Journal of clinical pharmacy and therapeutics, 2022) Meta-analysis Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis (Pharmaceutical biology, 2021) Meta-analysis Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases (Annals of palliative medicine, 2020) Meta-analysis Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis (Clinical and translational science, 2020) Systematic review Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis (Frontiers in medicine, 2021) Clinical trial publication Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (Oncoimmunology, 2026) Clinical trial publication First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation (Chinese medical journal, 2026) Clinical trial publication Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313) (The oncologist, 2025) CT.gov search · Cochrane · PubMed	DGIdb	—
GILTERITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYCHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
IDELALISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
IFOSFAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
IMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IPILIMUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
IRINOTECAN HYDROCHLORIDE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IXAZOMIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
LAPATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
LENVATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
LEUCOVORIN CALCIUM Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
LORLATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXSALEN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLENE BLUE ANHYDROUS Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIRDAMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOMYCIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 4 Meta-analysis 190 Trial pubs 109 RCT View evidence Registry trials NCT00024271 — Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer (UNKNOWN) PHASE2 NCT00004209 — Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (UNKNOWN) PHASE3 NCT04200417 — Chemoembolization for Lung Tumors (COMPLETED) PHASE1 NCT00148395 — Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. (COMPLETED) PHASE3 NCT01953406 — The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma (WITHDRAWN) PHASE2 NCT00003159 — Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer (COMPLETED) PHASE3 NCT05672108 — Phase II Trial of Lung Chemoemobolization (RECRUITING) PHASE2 NCT00128037 — Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806) (COMPLETED) PHASE2 Published literature Cochrane review A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer (BMC cancer, 2022) Cochrane review [Kanglaite for Treating Advanced Non-small-cell Lung Cancer: A Systematic Review.] (Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2009) Meta-analysis The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature (British journal of cancer, 2001) Meta-analysis The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group (Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1999) Meta-analysis The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective (Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1996) Clinical trial publication Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial (JAMA oncology, 2021) Clinical trial publication Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair (Journal of the National Cancer Institute, 2016) Clinical trial publication Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011) Clinical trial publication Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Clinical trial publication Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010) Randomized controlled trial Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial (Complementary therapies in medicine, 2009) CT.gov search · Cochrane · PubMed	DGIdb	—
MITOTANE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
MITOXANTRONE HYDROCHLORIDE Repurposing via BRCA1	Small molecule	Approved	Strong	95	2 trials View evidence Registry trials NCT02467426 — Isolated Thoracic Perfusion (ITP-F) for MPM (COMPLETED) NCT04352413 — A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
NAFTIFINE HYDROCHLORIDE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NERATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
NICOTINE Repurposing via ALK	Small molecule	Approved	Strong	95	8 trials 7 Cochrane 13 Meta-analysis 51 Trial pubs 45 RCT View evidence Registry trials NCT00310141 — Computer-Assisted Counseling in Helping African American Smokers Stop Smoking (COMPLETED) NA NCT07111936 — Evaluating the Impact of CONNECT in a Multilingual Population (NOT_YET_RECRUITING) NA NCT01434342 — Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients (COMPLETED) EARLY_PHASE1 NCT03200236 — The Lung Screening, Tobacco and Health Project (COMPLETED) PHASE3 NCT00957424 — Acceptability of Less Harmful Alternatives to Cigarettes (COMPLETED) NA NCT04616768 — PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers (COMPLETED) PHASE3 NCT02658032 — Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP) (COMPLETED) NA NCT01176383 — Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers (COMPLETED) NA Published literature Cochrane review Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map (Addiction (Abingdon, England), 2026) Cochrane review Health impacts of passive exposure to alternative tobacco products: a systematic review (Respiratory medicine, 2026) Cochrane review Interventions for smoking cessation in people diagnosed with lung cancer (The Cochrane database of systematic reviews, 2019) Cochrane review A Systematic Review of Effects of Waterpipe Smoking on Cardiovascular and Respiratory Health Outcomes (Tobacco use insights, 2016) Cochrane review Benefits of E-Cigarettes Among Heavy Smokers Undergoing a Lung Cancer Screening Program: Randomized Controlled Trial Protocol (JMIR research protocols, 2016) Meta-analysis Tar level of cigarettes smoked and risk of smoking-related diseases (Inhalation toxicology, 2018) Meta-analysis Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence (Molecular psychiatry, 2018) Meta-analysis Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis (EBioMedicine, 2016) Meta-analysis Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence (Translational psychiatry, 2015) Meta-analysis Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans (Molecular psychiatry, 2016) Systematic review Evidence on vaping e-cigarettes as a risk factor for cancer: A systematic review (Journal of cancer policy, 2025) Systematic review Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review (Clinical lung cancer, 2024) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NIRAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 4 Trial pubs 1 RCT View evidence Registry trials NCT04701307 — Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas (ACTIVE_NOT_RECRUITING) PHASE2 NCT03654833 — Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (UNKNOWN) PHASE2 NCT03308942 — Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants (COMPLETED) PHASE2 NCT05169437 — Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (TERMINATED) PHASE2 NCT05455424 — Niraparib Efficacy in Patient With Unresectable Mesothelioma (COMPLETED) PHASE2 NCT03830918 — Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT03891615 — Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer (UNKNOWN) PHASE1 NCT05718323 — Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RECRUITING) PHASE2 Published literature Clinical trial publication Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial (Clinical cancer research : an official journal of the American Association for Cancer Research, 2024) Clinical trial publication JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer (Cancer, 2022) Clinical trial publication Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021) Clinical trial publication The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial (The Lancet. Oncology, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
NIVOLUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OCTREOTIDE ACETATE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 1 Cochrane 19 Trial pubs 5 RCT View evidence Registry trials NCT06419179 — Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (ENROLLING_BY_INVITATION) PHASE2 NCT02734004 — A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT06217757 — Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC (RECRUITING) PHASE1, PHASE2 NCT05975944 — Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer (UNKNOWN) PHASE1, PHASE2 NCT05623319 — Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (RECRUITING) PHASE2 NCT03155620 — Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (ACTIVE_NOT_RECRUITING) PHASE2 NCT02769962 — Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (COMPLETED) PHASE1, PHASE2 NCT04939662 — Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (COMPLETED) PHASE2 Published literature Cochrane review First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis (Frontiers in oncology, 2024) Systematic review Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis (Frontiers in oncology, 2025) Clinical trial publication Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (JCO precision oncology, 2026) Clinical trial publication Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study (JCO precision oncology, 2025) Clinical trial publication Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial (Targeted oncology, 2024) Randomized controlled trial Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial (British journal of cancer, 2024) Randomized controlled trial Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial (Lung cancer (Amsterdam, Netherlands), 2022) Randomized controlled trial Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial (Clinical cancer research : an official journal of the American Association for Cancer Research, 2022) Randomized controlled trial Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) (Lung cancer (Amsterdam, Netherlands), 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
OSIMERTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
OXALIPLATIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 3 Cochrane 4 Meta-analysis 42 Trial pubs 15 RCT View evidence Registry trials NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT05576077 — A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (TERMINATED) PHASE1 NCT04043195 — Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT03250832 — Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (COMPLETED) PHASE1 NCT06131840 — A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (RECRUITING) PHASE1 NCT06835569 — A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations (RECRUITING) PHASE1 NCT03009058 — Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (TERMINATED) PHASE1, PHASE2 NCT06047379 — Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model (Health technology assessment (Winchester, England), 2013) Cochrane review [Vinorelbine plus oxaliplatin versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: a systematic review] (Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010) Cochrane review KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (Ontario health technology assessment series, 2010) Meta-analysis The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis (International immunopharmacology, 2022) Meta-analysis The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets (Oncotarget, 2017) Meta-analysis Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer (Medicine, 2015) Meta-analysis [Oxaliplatin: the first DACH platinum in clinical practice] (Bulletin du cancer, 1997) Systematic review Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis (Frontiers in oncology, 2019) Clinical trial publication Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial (JNCI cancer spectrum, 2025) Clinical trial publication Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025) Clinical trial publication Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01) (Anticancer research, 2021) Clinical trial publication A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC) (Cancer chemotherapy and pharmacology, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
PACLITAXEL PROTEIN-BOUND Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT04222972 — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (TERMINATED) PHASE3 NCT07271602 — A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (NOT_YET_RECRUITING) PHASE2 NCT05295212 — Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB (RECRUITING) PHASE2 NCT05500092 — An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT05867121 — A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (COMPLETED) PHASE1 NCT06449209 — Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (ACTIVE_NOT_RECRUITING) PHASE2 NCT01814163 — Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab (COMPLETED) NCT07618793 — Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma (NOT_YET_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
PALBOCICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
PANITUMUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
PANOBINOSTAT Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
PAZOPANIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMBROLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
PEMETREXED DISODIUM Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
PENPULIMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
PERMETHRIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
PERTUZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	21 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PIRTOBRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
PONATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
PRALSETINIB Repurposing via CCDC6	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PRAZOSIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PREDNISONE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
RABEPRAZOLE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMUCIRUMAB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
REGORAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIBRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
REPOTRECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
RESVERATROL Repurposing via BRCA1	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis View evidence Published literature Cochrane review Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis (Frontiers in nutrition, 2025) Meta-analysis Resveratrol in lung cancer- a systematic review (Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
RIBOCICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBOFLAVIN Repurposing via BRCA1	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006) Clinical trial publication [Chemoprevention in the high incidence area of lung cancer] (Zhonghua zhong liu za zhi [Chinese journal of oncology], 1989) CT.gov search · Cochrane · PubMed	DGIdb	—
RIFAMPIN Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
RILZABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
RITLECITINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
RITLECITINIB TOSYLATE Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ROMIDEPSIN Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
RUCAPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT03654833 — Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (UNKNOWN) PHASE2 NCT03845296 — Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (COMPLETED) PHASE2 NCT04171700 — A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (TERMINATED) PHASE2 NCT02711137 — Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (TERMINATED) PHASE1, PHASE2 NCT03958045 — Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma (COMPLETED) PHASE2 NCT07674368 — Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed (NOT_YET_RECRUITING) PHASE4 NCT04209595 — PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (COMPLETED) PHASE1, PHASE2 NCT03559049 — Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer (TERMINATED) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
RUXOLITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
SACITUZUMAB GOVITECAN Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 4 Cochrane 1 Meta-analysis 8 Trial pubs 1 RCT View evidence Registry trials NCT04794699 — Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (ACTIVE_NOT_RECRUITING) PHASE1 NCT07339059 — Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (RECRUITING) PHASE2 NCT06477419 — A Study of Sacituzumab Govitecan in People With Mesothelioma (RECRUITING) PHASE2 NCT05633667 — Study of Novel Treatment Combinations in Patients With Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01631552 — Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (COMPLETED) PHASE1, PHASE2 NCT07393555 — Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) (NOT_YET_RECRUITING) PHASE2 NCT03337698 — A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (TERMINATED) PHASE1, PHASE2 NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (RECRUITING) PHASE3 Published literature Cochrane review Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis (Frontiers in pharmacology, 2025) Cochrane review TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes (Critical reviews in oncology/hematology, 2026) Cochrane review Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis (Frontiers in oncology, 2025) Cochrane review TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC) (Cancer treatment reviews, 2023) Clinical trial publication First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026) Clinical trial publication Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2-targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors (Drug metabolism and disposition: the biological fate of chemicals, 2025) Clinical trial publication The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan (Clinical lung cancer, 2025) Clinical trial publication Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
SAPANISERTIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
SELPERCATINIB Repurposing via CCDC6	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SELUMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ALK	Small molecule	Approved	Strong	95	8 trials 6 Trial pubs View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT00807755 — Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors (TERMINATED) PHASE1 NCT01175096 — Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (UNKNOWN) PHASE1, PHASE2 NCT02061800 — CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT00375245 — Rapamycin With Grapefruit Juice for Advanced Malignancies (COMPLETED) PHASE1 NCT02920450 — Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) (TERMINATED) PHASE1, PHASE2 NCT00921310 — Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (TERMINATED) PHASE1, PHASE2 NCT02432560 — Safety and Durability of Sirolimus for Treatment of LAM (RECRUITING) Published literature Clinical trial publication A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib (Lung cancer (Amsterdam, Netherlands), 2017) Clinical trial publication Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial (Blood, 2015) Clinical trial publication Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population (Oncotarget, 2013) Clinical trial publication A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors (Japanese journal of clinical oncology, 2010) Clinical trial publication Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
SORAFENIB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
SORAFENIB TOSYLATE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SUGEMALIMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SUNVOZERTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
TACROLIMUS ANHYDROUS Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TALAZOPARIB Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 6 Trial pubs 1 RCT View evidence Registry trials NCT04591431 — The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (UNKNOWN) PHASE2 NCT02567396 — Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (WITHDRAWN) PHASE1 NCT03672773 — Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT01286987 — Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (COMPLETED) PHASE1 NCT03377556 — Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (COMPLETED) PHASE2 NCT04462809 — Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (UNKNOWN) PHASE2 NCT02154490 — Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (COMPLETED) NCT04173507 — Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (COMPLETED) PHASE2 Published literature Clinical trial publication Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929 (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025) Clinical trial publication Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study (JCO precision oncology, 2024) Clinical trial publication Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023) Clinical trial publication Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G (Clinical lung cancer, 2021) Clinical trial publication Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol (The Lancet. Oncology, 2020) CT.gov search · Cochrane · PubMed	DGIdb	—
TALETRECTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMOXIFEN CITRATE Repurposing via BRCA1	Small molecule	Approved	Strong	95	4 trials View evidence Registry trials NCT00002608 — Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (COMPLETED) PHASE2 NCT00847366 — Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma (COMPLETED) NA NCT00999921 — Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer (COMPLETED) PHASE4 NCT00896155 — Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
TAZEMETOSTAT Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TAZOBACTAM Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TEMOZOLOMIDE Repurposing via ATR	Small molecule	Approved	Strong	95	—	DGIdb	—
TEMSIROLIMUS Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TEPOTINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
THIABENDAZOLE Repurposing via BRCA1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TIRABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
TISLELIZUMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
TIVOZANIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TOPOTECAN HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
TORIPALIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TOVORAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TRAMETINIB DIMETHYL SULFOXIDE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
TRASTUZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TREMELIMUMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALPROIC ACID Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
VANDETANIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
VEMURAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
VENETOCLAX Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
VINBLASTINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
VINCRISTINE SULFATE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
VINORELBINE Repurposing via BRCA1	Small molecule	Approved	Strong	95	8 trials 32 Cochrane 37 Meta-analysis 601 Trial pubs 253 RCT View evidence Registry trials NCT00312819 — Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer (COMPLETED) PHASE2, PHASE3 NCT03891173 — A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (TERMINATED) PHASE2 NCT02352948 — A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (COMPLETED) PHASE3 NCT00705549 — Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer (TERMINATED) PHASE2 NCT00001944 — Vinorelbine and XR9576 to Treat Cancer (COMPLETED) PHASE1 NCT02603003 — the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs (COMPLETED) PHASE1 NCT00522886 — Phase I Cetuximab and Concurrent Radio-chemotherapy (COMPLETED) PHASE1 NCT03456076 — A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE3 Published literature Cochrane review Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic review (Translational cancer research, 2026) Cochrane review A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer (Medicine, 2024) Cochrane review Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses (BMC cancer, 2024) Cochrane review Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer (Frontiers in pharmacology, 2022) Cochrane review A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer (BMC cancer, 2022) Meta-analysis Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis (BMJ open, 2022) Meta-analysis Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data (BMC pulmonary medicine, 2022) Systematic review Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis (Lung cancer (Amsterdam, Netherlands), 2019) Systematic review Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials (Cytotherapy, 2019) Systematic review Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review (Clinical oncology (Royal College of Radiologists (Great Britain)), 2019) Systematic review Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review (Expert review of anticancer therapy, 2018) Clinical trial publication Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis (European journal of cancer (Oxford, England : 1990), 2026) CT.gov search · Cochrane · PubMed	DGIdb	—
VORINOSTAT Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ZANUBRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	—	DGIdb	—
ZOLEDRONIC ACID ANHYDROUS Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ALK	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ALK	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
GSK126 Repurposing via ARID1A	Small molecule	Phase II	Emerging	50	—	DGIdb	—
M4344 Repurposing via ATR	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ALK	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

108 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Folate Natural product Human Study Alcohol and polymorphisms in genes involved in the metabolism of alcoho… Human Study High plasma homocysteine and low folate levels were observed in the pat…	Nutraceutical	Approved	Emerging	19	8 trials 13 RCT View evidence Registry trials NCT00343408 — AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer (COMPLETED) PHASE1 NCT01258127 — Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC) (UNKNOWN) NCT06447662 — A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (RECRUITING) PHASE1 NCT06385925 — A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (RECRUITING) PHASE1, PHASE2 NCT05116891 — A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors (COMPLETED) PHASE1, PHASE2 NCT03656549 — Dose Individualization of Pemetrexed - IMPROVE-I (COMPLETED) PHASE4 NCT01165021 — A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer (COMPLETED) PHASE2 NCT07405190 — Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC (NOT_YET_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin B12 Natural product Meta Analysis, Review Current data suggests an inverse association between serum vitamin D an… Meta Analysis Higher intake of vitamin C might have a protective effect against lung… Meta Analysis The results of this study indicated that vitamin E intake might decreas…	Nutraceutical	Phase III	Emerging	19	8 trials 1 Cochrane View evidence Registry trials NCT01258127 — Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC) (UNKNOWN) NCT01165021 — A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer (COMPLETED) PHASE2 NCT04265534 — KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (TERMINATED) PHASE2 NCT03950674 — Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study (COMPLETED) PHASE3 NCT00227019 — Phase 2 Trial of Bevacizumab in Combination With Pemetrexed (COMPLETED) PHASE2 NCT01257139 — Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments (COMPLETED) PHASE3 NCT01204307 — Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation (COMPLETED) PHASE2 NCT00609518 — A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Egcg Natural product Meta Analysis Both green tea and black tea were significantly associated with a reduc… Human Study Intakes of green leafy vegetables, β-carotene-rich vegetables, watermel… Human In Vitro A cordyceps sinensis extract has a pro-apoptic effect on human lung ade…	Food compound	Phase III	Emerging	16	7 trials View evidence Registry trials NCT00611650 — Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia (TERMINATED) PHASE2 NCT02577393 — Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy (UNKNOWN) PHASE2 NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 NCT06924749 — Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia (COMPLETED) PHASE2 NCT05758571 — Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients (UNKNOWN) PHASE1, PHASE2 NCT01317953 — Oral Green Tea Extract for Small Cell Lung Cancer (AVAILABLE) NCT00573885 — Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin C Natural product Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression… Cochrane review Vitamin and Mineral Supplements for the Primary Prevention of Cardiovas… Cochrane review https://pubmed.ncbi.nlm.nih.gov/35767665/	Nutraceutical	Phase II	Emerging	10	8 trials 10 Cochrane 9 Meta-analysis 8 Trial pubs 6 RCT View evidence Registry trials NCT00005825 — Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (UNKNOWN) PHASE2 NCT03146962 — High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies (COMPLETED) PHASE2 NCT02905591 — A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (ACTIVE_NOT_RECRUITING) PHASE2 NCT02420314 — Pharmacological Ascorbate for Lung Cancer (COMPLETED) PHASE2 NCT03307785 — Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (COMPLETED) PHASE1 NCT03799094 — Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations (UNKNOWN) PHASE1, PHASE2 NCT02931942 — Changing Over Time of Ascorbic Acid After Chemotherapy (UNKNOWN) NCT02655913 — Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer (COMPLETED) PHASE1, PHASE2 Published literature Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2023) Cochrane review Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (JAMA, 2022) Cochrane review Cochrane review Drugs for preventing lung cancer in healthy people (The Cochrane database of systematic reviews, 2020) Cochrane review Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (The Cochrane database of systematic reviews, 2017) Systematic review Diet as a Factor Supporting Lung Cancer Treatment-A Systematic Review (Nutrients, 2023) Systematic review Vitamin C intake and multiple health outcomes: an umbrella review of systematic reviews and meta-analyses (International journal of food sciences and nutrition, 2022) Clinical trial publication Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer (Redox biology, 2022) Clinical trial publication Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 (JAMA ophthalmology, 2014) Clinical trial publication [The impact of ascorbic acid on the concentrations of antioxidative vitamins in the plasma of patients with non-small cell lung cancer undergoing first-line chemotherapy] (Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2013) Clinical trial publication Vitamin E supplementation may transiently increase tuberculosis risk in males who smoke heavily and have high dietary vitamin C intake (The British journal of nutrition, 2008) Clinical trial publication Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA adducts and potential cancer risk in female smokers (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin D3 Natural product Cochrane review Drugs for preventing lung cancer in healthy people Clinical trial publication Effects of multimodal prehabilitation on muscle size, myosteatosis, and… Clinical trial publication Safety and Tolerability of Targeted Medical Nutrition for Cachexia in N…	Nutraceutical	Phase III	Emerging	10	8 trials 1 Cochrane 1 Meta-analysis 3 Trial pubs 2 RCT View evidence Registry trials NCT00690924 — Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer (COMPLETED) NA NCT01631526 — Vitamin D Loading Dose in Advanced Lung Cancer (COMPLETED) NA NCT06209229 — Role of Neutrophils and Electro-bioluminescence in the Rehabilitation (COMPLETED) PHASE1 NCT00285675 — Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 (UNKNOWN) PHASE2 NCT01409681 — A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer (TERMINATED) NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 NCT00365105 — Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer (COMPLETED) PHASE3 NCT00794547 — Phase I/II Calcitriol in Lung Cancer (TERMINATED) PHASE1, PHASE2 Published literature Cochrane review Drugs for preventing lung cancer in healthy people (The Cochrane database of systematic reviews, 2020) Clinical trial publication Effects of multimodal prehabilitation on muscle size, myosteatosis, and dietary intake of surgical patients with lung cancer - a randomized feasibility study (Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2021) Clinical trial publication Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial (Nutrition and cancer, 2020) Clinical trial publication Vitamin D intake and lung cancer risk in the Women's Health Initiative (The American journal of clinical nutrition, 2013) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Cyclohexane-1,2,3,4,5,6-Hexol Natural product Human Study Myo-inositol has a chemopreventive effect against lung cancer, resultin…	Food compound	Preclinical	Moderate	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com, GreenMedInfo	PubChem GreenMedInfo Examine.com
Magnesium Natural product Cochrane review Pharmacological interventions for preventing atrial fibrillation after… Cochrane review https://pubmed.ncbi.nlm.nih.gov/35767665/ Cochrane review Magnesium intake and lung cancer risk: A systematic review and meta-ana…	Nutraceutical	Approved	Emerging	10	8 trials 3 Cochrane 5 Meta-analysis 11 Trial pubs View evidence Registry trials NCT01262560 — Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer (COMPLETED) PHASE2 NCT05265091 — A Study of KL590586 in Patients With Advanced Solid Tumors (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT07149649 — Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (NOT_YET_RECRUITING) PHASE2, PHASE3 NCT05121948 — A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (TERMINATED) PHASE1 NCT02883790 — Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients (TERMINATED) NA NCT05172739 — Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC (RECRUITING) PHASE4 NCT06209229 — Role of Neutrophils and Electro-bioluminescence in the Rehabilitation (COMPLETED) PHASE1 NCT00042770 — Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer (COMPLETED) PHASE3 Published literature Cochrane review Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis (European journal of clinical pharmacology, 2022) Cochrane review Cochrane review Magnesium intake and lung cancer risk: A systematic review and meta-analysis (International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2021) Meta-analysis Investigating Causal Associations of Circulating Micronutrients Concentrations with the Risk of Lung Cancer: A Mendelian Randomization Study (Nutrients, 2022) Meta-analysis Serum magnesium levels and lung cancer risk: a meta-analysis (World journal of surgical oncology, 2018) Meta-analysis Postoperative atrial fibrillation prophylaxis after lung surgery: systematic review and meta-analysis (The Annals of thoracic surgery, 2014) Clinical trial publication Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib) (Cancer chemotherapy and pharmacology, 2025) Clinical trial publication Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients (The oncologist, 2025) Clinical trial publication Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study (International journal of clinical oncology, 2020) Clinical trial publication A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3) (Lung cancer (Amsterdam, Netherlands), 2018) Clinical trial publication Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study (Japanese journal of clinical oncology, 2013) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Garlic Natural product Human Study Raw garlic consumption is associated with reduced risk of lung cancer i…	Food compound	Preclinical	Emerging	10	45 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin E Natural product Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression… Cochrane review Vitamin and Mineral Supplements for the Primary Prevention of Cardiovas… Cochrane review https://pubmed.ncbi.nlm.nih.gov/35767665/	Nutraceutical	Phase III	Emerging	10	8 trials 12 Cochrane 9 Meta-analysis 22 Trial pubs 19 RCT View evidence Registry trials NCT01871454 — Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers (UNKNOWN) PHASE2 NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (RECRUITING) PHASE2 NCT00002586 — 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer (COMPLETED) PHASE2 NCT03470857 — Oxidoreductive Balance and Lysosomal Activity in Cancer Patients. (COMPLETED) NCT03307785 — Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (COMPLETED) PHASE1 NCT04919369 — All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (ACTIVE_NOT_RECRUITING) PHASE1 NCT00003599 — Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer (WITHDRAWN) PHASE3 NCT00006349 — Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer (COMPLETED) PHASE3 Published literature Cochrane review Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (The Cochrane database of systematic reviews, 2023) Cochrane review Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (JAMA, 2022) Cochrane review Cochrane review Drugs for preventing lung cancer in healthy people (The Cochrane database of systematic reviews, 2020) Cochrane review Selenium for preventing cancer (The Cochrane database of systematic reviews, 2018) Meta-analysis Association of various dietary habits and risk of lung cancer: an updated comprehensive literature review (Tumori, 2020) Meta-analysis Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (The Cochrane database of systematic reviews, 2017) Meta-analysis Association of dietary vitamin E intake with risk of lung cancer: a dose-response meta-analysis (Asia Pacific journal of clinical nutrition, 2017) Systematic review Vitamin E intake and multiple health outcomes: an umbrella review (Frontiers in public health, 2023) Systematic review Diet as a Factor Supporting Lung Cancer Treatment-A Systematic Review (Nutrients, 2023) Clinical trial publication Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 (JAMA ophthalmology, 2014) Clinical trial publication Vitamin E supplementation may transiently increase tuberculosis risk in males who smoke heavily and have high dietary vitamin C intake (The British journal of nutrition, 2008) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Cochrane review Effects of omega-3 fatty acids on cancer risk: a systematic review Meta-analysis Omega-3 Fatty Acids Increase Weight and Quality of Life Scores in Patie… Systematic review Should omega-3 fatty acids be used for adjuvant treatment of cancer cac…	Nutraceutical	Phase III	Emerging	10	8 trials 1 Cochrane 1 Meta-analysis 3 Trial pubs View evidence Registry trials NCT02515032 — Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia (COMPLETED) NA NCT04907864 — Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE) (UNKNOWN) PHASE2 NCT07042724 — Exercise and Nutrition on Early-stage NSCLC Outcomes: the STARLighT Study (RECRUITING) NA NCT06128694 — Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients (UNKNOWN) PHASE3 NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients (RECRUITING) NA NCT00851448 — Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients (TERMINATED) NA NCT01259284 — Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer (TERMINATED) PHASE2, PHASE3 NCT06531460 — Nutritional Therapy Enriched With Omega-3 in Patients With Lung Resection (RECRUITING) NA Published literature Cochrane review Effects of omega-3 fatty acids on cancer risk: a systematic review (JAMA, 2006) Meta-analysis Omega-3 Fatty Acids Increase Weight and Quality of Life Scores in Patients With Advanced Non-Small Cell Lung Cancer and Cancer Cachexia: A Meta-Analysis (Integrative cancer therapies, 2024) Systematic review Should omega-3 fatty acids be used for adjuvant treatment of cancer cachexia? (Clinical nutrition ESPEN, 2018) Clinical trial publication Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28 (JAMA ophthalmology, 2022) Clinical trial publication Is preoperative protein-rich nutrition effective on postoperative outcome in non-small cell lung cancer surgery? A prospective randomized study (Journal of cardiothoracic surgery, 2016) Clinical trial publication Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial (JAMA, 2013) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Olive Oil Natural product Clinical trial publication Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in… Human: Case Report, Human Study Thymoquinone plus immunotherapy in extra-pulmonary neuroendocrine carci… Human Study A pilot study of a grape seed procyanidin extract for lung cancer chemo…	Nutraceutical	Preclinical	Emerging	10	3 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT03785808 — Reducing Insulin, Growth Hormones, and Tumors (TERMINATED) NA NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients (RECRUITING) NA NCT04965129 — Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet (UNKNOWN) NA Published literature Clinical trial publication Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in Smokers (Cancer prevention research (Philadelphia, Pa.), 2020) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Curcumin Natural product Meta-analysis Investigating the Potential of Curcumin in the Treatment of Nonsmall Ce… Meta-analysis Resveratrol in lung cancer- a systematic review Human In Vitro Bisdemethoxycurcumin induced changes in gene expression that may reveal…	Food compound	Phase III	Emerging	7	5 trials 2 Meta-analysis View evidence Registry trials NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy (RECRUITING) NA NCT01048983 — Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) (WITHDRAWN) PHASE1, PHASE2 NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 NCT03598309 — Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (ACTIVE_NOT_RECRUITING) PHASE2 NCT02321293 — A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (UNKNOWN) PHASE1 Published literature Meta-analysis Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta-Analysis, Network Pharmacology, and Mendelian Randomization (Phytotherapy research : PTR, 2025) Meta-analysis Resveratrol in lung cancer- a systematic review (Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2016) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Grape Seed Extract Natural product Human Study A pilot study of a grape seed procyanidin extract for lung cancer chemo… Human Study Grape seed procyanidin extract mediates antineoplastic effects against… Human Study The anti-inflammatory effects of GSE/LP in the lung microenvironment an…	Botanical	Phase II	Emerging	7	1 trials View evidence Registry trials NCT04515004 — Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Reishi Natural product Clinical trial publication Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality o… Human Study Turkey tail (Coriolus versicolor) mushroom contains compounds which imp…	Mushroom	Phase II	Emerging	7	3 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT06356701 — Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC (UNKNOWN) PHASE1 NCT02844114 — Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy (UNKNOWN) PHASE2 NCT07554885 — Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation (NOT_YET_RECRUITING) NA Published literature Clinical trial publication Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non-Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial (Integrative cancer therapies, 2020) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Berberine Natural product Clinical trial publication Protective effects of berberine on radiation-induced lung injury via in… Meta Analysis, Review Berberine exerted anti-tumor effects in a variety of tumors in vivo. Human In Vitro Berberine can significantly inhibit the activity of N-acetyltransferase…	Botanical	Phase II	Emerging	7	1 trials 1 Cochrane 1 Meta-analysis 1 Trial pubs View evidence Registry trials NCT03486496 — Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (UNKNOWN) PHASE2 Published literature Clinical trial publication Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer (European journal of cancer (Oxford, England : 1990), 2008) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Cochrane review Therapeutic effects and safety of resveratrol for lung cancer: an updat… Meta-analysis Resveratrol in lung cancer- a systematic review Human In Vitro Berberine can significantly inhibit the activity of N-acetyltransferase…	Food compound	Preclinical	Emerging	7	1 Cochrane 1 Meta-analysis View evidence Published literature Cochrane review Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis (Frontiers in nutrition, 2025) Meta-analysis Resveratrol in lung cancer- a systematic review (Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2016) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Cordyceps Natural product Human In Vitro A cordyceps sinensis extract has a pro-apoptic effect on human lung ade… Animal Study, In Vitro Study Angelica sinensis suppresses human lung adenocarcinoma A549 cell metast…	Mushroom	Phase III	Emerging	7	2 trials 1 Cochrane 1 Meta-analysis View evidence Registry trials NCT03479294 — Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection (TERMINATED) NCT03745261 — Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Egcg Natural product Meta Analysis Tea drinking could be a protective factor in lung cancer. Meta Analysis Both green tea and black tea were significantly associated with a reduc… Human Study Intakes of green leafy vegetables, β-carotene-rich vegetables, watermel…	Food compound	Phase III	Emerging	7	7 trials View evidence Registry trials NCT00611650 — Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia (TERMINATED) PHASE2 NCT02577393 — Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy (UNKNOWN) PHASE2 NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 NCT06924749 — Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia (COMPLETED) PHASE2 NCT05758571 — Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients (UNKNOWN) PHASE1, PHASE2 NCT01317953 — Oral Green Tea Extract for Small Cell Lung Cancer (AVAILABLE) NCT00573885 — Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Black Seed Oil Natural product Human: Case Report, Human Study Thymoquinone plus immunotherapy in extra-pulmonary neuroendocrine carci… Meta Analysis Both green tea and black tea were significantly associated with a reduc… Human Study Black tea intake was associated with lower risk of lung cancer.	Botanical	Phase I	Emerging	7	1 trials View evidence Registry trials NCT05262556 — NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas (ACTIVE_NOT_RECRUITING) PHASE1 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Astragalus Natural product Systematic review Aidi injection as adjunctive treatment to gemcitabine-based chemotherap… Systematic review Evidence of Astragalus injection combined platinum-based chemotherapy i… Systematic review Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-s…	TCM herb	Phase III	Emerging	7	3 trials 4 Trial pubs 2 RCT View evidence Registry trials NCT01802021 — Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients (UNKNOWN) PHASE2, PHASE3 NCT02737735 — The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation (UNKNOWN) PHASE1 NCT06674252 — A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery (RECRUITING) NA Published literature Systematic review Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis (Pharmaceutical biology, 2021) Systematic review Evidence of Astragalus injection combined platinum-based chemotherapy in advanced nonsmall cell lung cancer patients: A systematic review and meta-analysis (Medicine, 2019) Systematic review Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines (Journal of ethnopharmacology, 2018) Clinical trial publication Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial (Integrative cancer therapies, 2025) Clinical trial publication Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival (Medical oncology (Northwood, London, England), 2012) Clinical trial publication Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients (Cancer chemotherapy and pharmacology, 2009) Clinical trial publication [Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer] (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2003) CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Niacin Natural product Meta Analysis, Review Current data suggests an inverse association between serum vitamin D an… Meta Analysis Higher intake of vitamin C might have a protective effect against lung… Meta Analysis Review: there is a consistently strong inverse correlations with solar…	Nutraceutical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Probiotics Natural product Human Study The present study highlighted that C. butyricum reduced chemotherapy-in…	Probiotic	Preclinical	Emerging	7	—	GreenMedInfo	GreenMedInfo
Melatonin Natural product Human Study A short hydration regimen with 20 mEq of magnesium supplementation is s… Human Study High-volume hydration and magnesium supplementation can reduce the rena… Human In Vitro Melatonin in combination with HDAC inhibitors may be a novel therapeuti…	Nutraceutical	Preclinical	Emerging	7	—	GreenMedInfo	PubChem GreenMedInfo
Cannabidiol Natural product Cannabidiol effects in stem cells: A systematic review Cannabis-based medicines and medical cannabis for adults with cancer pa…	Food compound	Preclinical	Emerging	2	—	GreenMedInfo	PubChem GreenMedInfo
Staurosporine Natural product Design, synthesis, and antiproliferative activity of novel thiazole-bas… Chemical Composition and Anti-Lung Cancer Activities of Melaleuca quinq… An innovative approach to development of new pyrazolylquinolin-2-one hy…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alvocidib Natural product RNA sequencing identifies lung cancer lineage and facilitates drug repo… CKAP2L Promotes Non-Small Cell Lung Cancer Progression through Regulati… A new advanced in silico drug discovery method for novel coronavirus (S…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Thiourea Natural product Thiourea Derivatives for the Potential Treatment of Lung Cancer via the… Label-Free Imaging Immunosensor Based on Nickel-Manganese Double Hydrox… Urea-sugar and thiourea-sugar diastereomers: synthesis, crystal structu…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Erlotinib Natural product Human Study Proton pump inhibitors reduce the survival of advanced lung cancer pati…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pazopanib Natural product MVGAE: A Multi-View Graph Auto-Encoder Model for Drug Prediction of Non… An LC-MS/MS-Based Quantification of Intracellular Anlotinib Reveals Exp… Multi-omics integration reveals CYP2B6 as a central node in the molecul…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Midostaurin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Seliciclib Natural product The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti… Unraveling the molecular landscape of non-small cell lung cancer: Integ… Therapeutic efficacy of cyclin-dependent kinase inhibition in combinati…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Semaxanib Natural product Sunitinib: from rational design to clinical efficacy Semaxanib (SUGEN)	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dactolisib Natural product Intrinsic resistance to RAS inhibitors is driven by dysregulation of KR… Characterization of the BH1406 non-small cell lung cancer (NSCLC) cell… Repurposing of sericin combined with dactolisib or vitamin D to combat…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Schisandrin B Natural product [Retracted] Schisandrin B inhibits epithelial‑mesenchymal transition an… Schisandrin B inhibits epithelial‑mesenchymal transition and stemness o… Enhanced antitumour efficacy of functionalized doxorubicin plus schisan…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Sb590885 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lactoquinomycin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lestaurtinib Natural product Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Prol… Perturbation of the mutated EGFR interactome identifies vulnerabilities…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Imatinib Natural product A systematic review of non-standard dosing of oral anticancer therapies Secondary malignancies in chronic myeloid leukemia patients after imati… Will targeted therapy hold its promise? An evidence-based review	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
A-443654 Natural product Integrative pharmacogenomics revealed three subtypes with different imm… A new advanced in silico drug discovery method for novel coronavirus (S…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lenvatinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Fisetin Natural product Fisetin-loaded Nanoemulsion and Fecal Microbiome Extract Enhance In Vit… Evaluation of the association between sex-linked genes and treatment re… Investigation on the antitumor effects of fisetin extracted from Hedyot…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Apigenin Natural product Dietary intake of selected flavonols, flavones, and flavonoid-rich food…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Chrysin Natural product Synergistic induction of apoptosis in lung cancer cells via TOP2A targe… Chitosan-functionalized mesoporous silica nanoparticles co-loaded with… Metabolism-targeted therapy in NSCLC - A new theranostics inhalation ap…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
12H-indolo[2,1-a]beta-carbolin-5-ium-13-one chloride Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Palbociclib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Gw607117x Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Hymenialdisine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Debromohymenialdisine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Cyclohexane-1,2,3,4,5,6-Hexol Natural product Human Study Myo-inositol has a chemopreventive effect against lung cancer, resultin…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
5,7-dihydroxy-3-(4-hydroxyphenyl)chromone Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Naringenin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Luteolin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Ginsenosides Natural product Meta Analysis, Review The effect of ginsenoside Rg3 combined with chemotherapy on immune func… Human Study Ginsenoside Rg3 could be used as a new regimen to delay acquired resist…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flavonoids Natural product Human Study The risk of lung cancer related to dietary intake of flavonoids. Human Study This study provides further support for a beneficial effect of flavonoi… Animal Study, In Vitro Study Anti-proliferation effects of isorhamnetin on lung cancer cells in vitr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Soy Natural product Meta Analysis "Soy intake is associated with lower lung cancer risk." Human Study Isoflavone intake was associated with a decreased risk of lung cancer. Human Study Mortality from Lung Cancer, Breast Cancer and Ischemic Heart Disease is…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cucurbitacin B Natural product Human Study Cucurbitacin B significantly reduced the frequency of immature myeloid… Animal Study, In Vitro Study Cucumber-derived nanovesicles containing cucurbitacin B for non-small c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Black Tea Natural product Meta Analysis Both green tea and black tea were significantly associated with a reduc… Meta Analysis Tea drinking could be a protective factor in lung cancer. Human Study Black tea intake was associated with lower risk of lung cancer.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cruciferous Vegetables Natural product Human Study Consumption of a diet rich in cruciferous vegetables may reduce the ris… Human Study Cruciferous vegetable intake may be associated with a reduction in lung… Human Study Intakes of green leafy vegetables, β-carotene-rich vegetables, watermel…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Water: Deuterium Depleted Natural product Human Study DDW was administered as an oral anticancer agent in addition to convent… Human Study Intakes of green leafy vegetables, β-carotene-rich vegetables, watermel… Animal Study, Human Study The median survival time of patients in the deuterium depleted water co…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Isoflavones Natural product Human Study Isoflavone intake was associated with a decreased risk of lung cancer. Human Study This study provides further support for a beneficial effect of flavonoi…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Anthocyanins Natural product Human Study The risk of lung cancer related to dietary intake of flavonoids. Human Study This study provides further support for a beneficial effect of flavonoi…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Beta-Elemene Natural product Animal Study, In Vitro Study FBP1 induced by β-elemene enhances the sensitivity of gefitinib in lung…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fruit: All Natural product Meta Analysis The associations of fruit and vegetable intake with lung cancer risk in… Human Study A moderate level of fruit consumption is associated with a decreased ri…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Isothiocyanates Natural product Human Study Consumption of a diet rich in cruciferous vegetables may reduce the ris… Human Study Cruciferous vegetable intake may be associated with a reduction in lung…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hydrogen: Molecular Natural product Human Study Hydrogen therapy can be used to control tumor progression and alleviate… Human Study Residential radon may have a role in the molecular signature of lung ca… Human Study Two weeks of hydrogen inhalation can significantly reverse adaptive and…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carotenoids Natural product Human Study Intakes of green leafy vegetables, β-carotene-rich vegetables, watermel… Human Study Several dietary antioxidants found in common food sources may protect a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Medicinal Mushrooms Natural product Human Study Long-term use of combined conventional medicine and Chinese herbal medi…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fucoidan Natural product Human Study Oral administration of oligo fucoidan improves the survival rate, quali…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flaxseed Natural product Human Study Phase II trial of flaxseed to prevent acute complications after chemora…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Soy Protein Natural product Meta Analysis "Soy intake is associated with lower lung cancer risk." Human Study C-reactive protein is a significant predictor of improved survival in p… Human Study Isoflavone intake was associated with a decreased risk of lung cancer.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gallic Acid Natural product Human In Vitro The anticancer/cytotoxic effect of a novel gallic acid derivative in no… Animal Study, In Vitro Study Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Antineoplaston AS2-1 (4:1 mixture of phenylacetic acid and phenylacetylglutamine) Natural product Human: Case Report "Phase I clinical studies of antineoplaston A5 injections." Human: Case Report A quick response of advanced cancer to chemoradiation therapy with anti… Human: Case Report Antineoplaston A2 has anticancer effects.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Silibinin Natural product Animal Study, In Vitro Study Combinations of grape seed procyanidin extract and milk thistle silymar…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Orchid Natural product Animal Study, In Vitro Study Erianin inhibits human lung cancer cell growth. Animal Study, In Vitro Study Erianin inhibits the progression of DDP-resistant lung adenocarcinoma.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gambogic Acid Natural product Animal Study, In Vitro Study Gambogic acid synergistically potentiates cisplatin-induced apoptosis i…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cucurbitacin E Natural product Human Study Cucurbitacin B significantly reduced the frequency of immature myeloid… Animal Study, In Vitro Study Cucumber-derived nanovesicles containing cucurbitacin B for non-small c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Baicalein Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cryptoxanthin Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Deguelin Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network